AquaBounty Technologies (NASDAQ:AQB) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.09) by 11.11 percent. This is a 20 percent increase over losses of $(0.10) per share from the same period last year. The company reported quarterly sales of $653.43 thousand which missed the analyst consensus estimate of $1.04 million by 37.17 percent. This is a 43.49 percent increase over sales of $455.40 thousand the same period last year.
AbbVie’s Leukemia Drug Falls Short In Late-Stage Study In Pretreated Blood Cancer Patients
AbbVie Inc (NASDAQ: ABBV) released data from its Phase 3 CANOVA study evaluating venetoclax (Venclexta/ Venclyxto) plus dexamethasone (VenDex) for patients with t(11;14)-positive relapsed or refractory (R/R) multiple myeloma who have received
